Natick

Rising sales and cost cuts boosted Boston Scientific's fourth-quarter profit significantly over 2012, the company reported.

Consolidations by some major employers in MetroWest caused the region's office vacancy rates to climb in the fourth quarter of 2013, according to data from global real estate broker Colliers International.

Life sciences firm SBH Sciences of Natick is linking up with a Georgia company in a collaborative venture to research and develop a class of drugs that can treat a variety of diseases, the two firms announced.

The flagship location in a chain of women's underwear stores closed last week, putting 60 out of work.

A ban on U.S. sales of the Guidezilla catheter made by Boston Scientific (BSX) went into effect yesterday after a federal appeals court ruled against BSX's petition for an interim stay.

The decision to take a company public isn't an easy one, said Paul Brannelly, senior vice president of finance and administration at Karyopharm Therapeutics in Natick. The money and time spent on activities related to public trading are considerable, according to Brannelly. Being public somewhat limits executives' ability to make quick business decisions. But Karyopharm, a clinical-stage drug company that is developing treatments for solid tumors as well as cancers of the blood, saw pursuing an initial public offering (IPO) this fall as an opportunity to shore up financing as it continues the lengthy clinical trial process that it hopes will lead to approval from the U.S. Food and Drug Administration (FDA).

With the Greater Boston commercial real estate market saying goodbye to 2013 with a strong fourth quarter,...

Bob's Discount Furniture, which has nearly 50 retail stores throughout the Northeast, including three in Central Massachusetts, is being sold to Bain Capital, the retailer announced today.

Karyopharm Therapeutics, a clinical-stage pharmaceutical company in Natick, has been added to the Russell 3000 and Russell 2000 indices as part of Russell Investments' fourth-quarter additions of companies that launched initial public offerings of stock, Karyopharm announced.

A panel of medical experts recommended Wednesday that federal health regulators approve Boston Scientific's stroke-prevention device.